X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of shares of common stock and pre-funded warrants Closed: US$155.3M raised · US$2.9 a share · Leerink Partners +2 Dealers: Leerink Partners (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead) Use of proceeds: Fund pivotal Phase 3 development of mavorixafor in chronic neutropenic disorders, G&A, capital expenditures, working capital and general corporate purposes | Oct 27, 2025 |
| Private placement of shares of common stock and pre-funded warrants Closed: US$85M raised · US$1.42 a share · Stifel Dealers: Stifel (lead) Buyers: Coastlands Capital (led the offering); Bain Capital Life Sciences (existing investor); New Enterprise Associates; BVF Partners LP; Deep Track Capital; Kalehua Capital; Nantahala Capital; Stonepine Capital Management; Trails Edge Capital Partners; Empery Asset Management, LP (existing investor); New Enterprise Associates (NEA) (existing investor) Use of proceeds: Continued development towards potential additional approval of mavorixafor in chronic neutropenia and commercialization in WHIM | Aug 13, 2025 |